Search results
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
Zacks via Yahoo News· 1 week agoThis week, the FDA rejected Merck's MRK and AbbVie’s ABBV regulatory filings seeking approvals for...
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
Zacks via Yahoo News· 1 week agoThe FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is...
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Zacks via Yahoo News· 1 week agoData from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo News· 1 month agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Zacks via Yahoo News· 1 month agoIt has been about a month since the last earnings report for Esperion Therapeutics (ESPR). Shares...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo News· 1 month agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo News· 1 month agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
‘Lives will be cut short’ if drug not given to women with breast cancer
PA Media: UK News via Yahoo News· 1 month agoHealth officials and pharmaceutical companies have been urged to urgently work together to make a...
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
Zacks via Yahoo News· 2 months agoAstraZeneca AZN announced its long-term plan to generate $80 billion in total revenues by 2030,...
AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
Yahoo Finance· 2 months agoAstraZeneca's (AZN) stock is up following its latest earnings report Thursday after the company...